drugset / Trial / NCT04247984
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
Phase 2
Completed
264 enrolled
Chinese Academy of Medical Sciences
Beijing Hospital · collabHenan Cancer Hospital · collabJiangsu Cancer Institute & Hospital · collabLiaoning Cancer Hospital & Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin®) plus mXELIRI compared with bevacizumab (Avastin®) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).
Timeline
- Start
- 2018-05-01
- Primary completion
- 2021-04-01
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CF | Unknown | 300 mg/m2 | Intravenous |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |